Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 2/20 | 0.36 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.33 |
| ▸ | RPS27 | P42677 | 1/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | DHFR | P00374 | 1/20 | 0.32 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL826074 | 0.83 | CHEK2 (0.39) | CHEK2AGPAT2RPS27MAPK8MAPK1 | |
| SCHEMBL826599 | 0.80 | TLR7 (0.37) | CHEK2 | |
| SCHEMBL826092 | 0.80 | CHEK2 (0.36) | CHEK2AGPAT2RPS27MAPK8MAPK1 | |
| SCHEMBL825682 | 0.78 | CHEK2 (0.35) | CHEK2AGPAT2RPS27MAPK8MAPK1 | |
| SCHEMBL825914 | 0.77 | CHEK2 (0.34) | CHEK2AGPAT2RPS27MAPK8MAPK1 | |
| SCHEMBL4425330 | 0.76 | CHEK2 (0.45) | CHEK2AGPAT2RPS27MAPK8MAPK1 | |
| SCHEMBL4414487 | 0.75 | MAP4K4 (0.45) | CHEK2MAPK8DHFR | |
| SCHEMBL4412814 | 0.67 | MET (0.40) | CHEK2MAPK1 | |
| SCHEMBL823709 | 0.67 | DHFR (0.43) | MAPK8MAPK1HSP90AA1DHFR | |
| SCHEMBL823761 | 0.66 | MKNK2 (0.38) | CHEK2AGPAT2MAPK8DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143394-B2 | Pyrido(3,2-d)pyrimidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20090324543-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090324543-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | PNPO, DPYD, PLPBP | CHEK2 1401/4885AGPAT2 2359/4885RPS27 3382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.